• End-stage renal disease (ESRD) is a debilitating medical condition of chronic kidney failure, also known as stage 5 chronic kidney disease. In ESRD the kidneys are permanently impaired, and patients may require dialysis or renal replacement therapy (RRT).
• Over the past 30 years, the prevalence of ESRD has increased worldwide. 1 By the end of 2008, around 2.3 million patients had received RRT. 2 Some 530,000 patients were living with a transplanted kidney, with the remainder receiving dialysis -either haemodialysis (HD; n=1,580,000) or peritoneal dialysis (PD; n=190,000). 2 • RRT is intensive and costly: according to the US Renal Data System 2012 3 , 1.3% of US Medicare patients had ESRD in 2010, yet they accounted for 7.5% of Medicare spending. 
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METHODS
• This project was a scoping review -an approach that examines the extent, range and nature of research activity in a given field; though similar to a systematic review, it does not define outcome parameters a priori.
• The search protocol defined the focus of review (patient population, relevant study designs and characteristics, outcomes of interest, perspectives and limitations); the search strategy; study selection criteria; data extraction methods; and data synthesis methods.
• The search strategy identified studies quantifying the economic burden of ESRD in adults in nine countries (Australia, Canada, France, Germany, Italy, Japan, Spain, UK and USA).
• • Results were de-duplicated and downloaded into a reference database.
• Two reviewers independently assessed the abstracts and included manuscripts for relevance. 
SEARCH RESULTS
Manuscripts for inclusion (n=40)
• We identified 2094 de-duplicated references from the combined search in which 57 manuscripts remained after review of titles/abstracts and 40 after full-text review ( Figure 1 ).
• Reports not published as peer-reviewed journal articles were not included in the review.
The authors thank Mick Arber for his expert insight in devising and running the searches. • The 40 included studies used a range of study designs: − 35 used existing data (e.g. published studies, hospital records, registries and databases) − Five were prospective studies.
Country
• There was a wide range of geographic settings (Table 1 ).
• The focus of the studies varied:
− ESRD in general (n=16) − Dialysis (n=16) − Transplant (n=8) − Diabetes (n=7). National-level data
STUDY RESULTS
• Two studies 4,6 reported total costs of ESRD (direct + indirect costs), whereas two 5,7 reported direct healthcare costs of ESRD only ( Table 2 ).
• The key cost driver of healthcare costs in the Canadian study 4 was HD undertaken in a medical centre; this was followed by the cost of ongoing transplant for a functioning kidney and then the cost of PD.
• In the Spanish study, 6 the main cost driver was that of dialysis treatment sessions.
National-level data: Dialysis
• The 2011 Spanish study 6 reported total (direct and indirect) annual dialysis costs for Spain. Costs in 2010 were €1327 million (HD), €109 million (PD).
• Three studies 4,6,7 reported total annual direct healthcare costs of dialysis (Table 3) ; they all found the economic burden of HD to be considerably higher than PD.
• Costs were not always limited solely to direct healthcare and indirect costs. 4, 6 For example, the 2012 English study 5 estimated that annual transport costs for a patient to attend dialysis was £50 million. These transport costs are often not captured in studies; also typically overlooked are social/community care costs, or personal costs associated with renovations to accommodate home dialysis.
National-level data: Transplant
• Only one study 6 reported total costs associated with transplant: for Spain, estimated to be €393 million.
• Five studies 4-8 reported total annual direct healthcare costs of transplant (Table 4 ).
• One study 7 provided data for both the UK and the USA.
• A breakdown of costs 5 shows that ongoing care after the first year is the biggest cost driver.
• This review identified a number of informative studies on the economic burden of ESRD, including costs split by transplant and dialysis care.
• However, significant gaps in the evidence base were identified that warrant further research:
− There were few national-level studies − Most studies were retrospective − Even robust and informative studies have so far taken a relatively narrow focus − Costs to non-healthcare budgets (e.g. social services) and to patients (lost productivity, out-ofpocket costs) should also be quantified.
• A prospective Europe-wide costing study of ESRD using a consistent methodology across all countries and taking a societal perspective would add significantly to the evidence base.
CONCLUSIONS Study Overview
• National-level total (direct + indirect), direct, and indirect costs are provided for ESRD, dialysis and transplant.
• Caution should be exercised in drawing comparisons across studies, given that − Each study took a different approach to costing − The resource use items on which analyses were based were not consistent − Methodologies and costing years varied.
• Table 5 
Patient-level data
• Ten studies 4,7,11-16 reported annual patient-level healthcare costs for ESRD (Table 5 ).
• A 2013 study 16 presented regression coefficients and cost multipliers associated with tobacco use status and each patient's demographic characteristics, diabetes treatment, complications, and comorbidities. ESRD treated with dialysis or kidney transplantation was associated with ~300% and ~500% higher costs, respectively.
• A comparison of costs between patients with/without DM reported that adjusted annual per-patient costs post-ESRD onset were significantly higher for patients with diabetes mellitus (DM) versus those without DM (p<0.0001). 17 • A 2006 study 18 noted substantial ESRD-related nonmedical costs that fell on employers. 
